The bactericidal activity of the proton pump inhibitors omeprazole and lansoprazole alone and in combination with a -lactam or macrolide antibiotic were investigated in vitro. Time-kill curves against Helicobacter pylori NCTC 11637 and a recent clinical isolate revealed significant concentration-dependent killing with all drugs other than amoxycillin. Combinations of proton pump inhibitor and erythromycin showed synergic activity. In contrast, proton pump inhibitor plus amoxycillin showed additive activity against the clinical isolate only. Bactericidal investigations of anti-helicobacter drugs in vitro may suggest optimum treatment strategies for this common infectious disease.
Introduction
Antimicrobial therapy is now commonly used to cure Helicobacter pylori infection. In its niche of gastric mucus, H. pylori is relatively protected from host antimicrobial defences. In order to cure this infection, antibiotics need to be bactericidal rather than bacteriostatic and able to kill every organism in the protected site. An analogy between the endocarditis model and H. pylori infection has been suggested for these reasons. 1 As well as exhibiting good in-vitro activity against H. pylori, therapies need all or some of the following additional properties: good dispersion in the stomach, the ability to penetrate mucus, lack of acquired resistance and stability over a wide range of pH. Although single agents are effective in vitro at killing H. pylori, eradication of the organism in patients with single agents is poor. Combination therapy probably attacks the organism through different mechanisms of action producing at least additive or perhaps synergic anti-helicobacter effects. Recent data from Coudron et al. 2 show that ampicillin is bactericidal against logarithmic phase culture of H. pylori whereas bismuth is active against stationary phase cultures using time-kill kinetic methods. The use of time-kill curves of H. pylori at achievable in-vivo drug concentrations measuring bactericidal activity over time (i.e. pharmacodynamics) may reveal differences in the effects of antimicrobial agents against H. pylori despite similar activities as measured by MIC. In this study, a -lactam, amoxycillin, and a macrolide, erythromycin, were investigated with the proton pump inhibitors (PPIs) omeprazole or lansoprazole for bactericidal and synergic activity against H. pylori.
Materials and methods

Bacteria
Two strains of H. pylori were examined: H. pylori NCTC 11637 and a recent clinical isolate, M98.
MIC determinations
Omeprazole and lansoprazole MICs were determined by agar dilution. Each drug was dissolved in dimethylsulphoxide to make a stock solution of 10,000 mg/L. This was subsequently diluted in distilled water and added to Mueller-Hinton agar (BBL, Cockeysville, MD, USA) with 5% horse blood (MHA) to give plates with final concentrations of 1-256 mg/L for each PPI. One microlitre of a 1 MacFarland standard of each H. pylori strain in Brain Heart Infusion broth (Oxoid, Basingstoke, UK) was inoculated on to the plates, which had been dried at 35°C for 1 h using a Multipoint replicator (Mast, Liverpool, UK). This gave an organism density of 7 10 4 cfu/mL. MHA plates with no drug were inoculated at the beginning and end of each set as growth control plates. All plates were incubated for 72 h at 35°C under microaerophilic conditions (Camp Gas Pak, Oxoid, Basingstoke, UK).
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Amoxycillin and erythromycin MICs were tested by swabbing the 1 MacFarland broth suspensions of each H. pylori strain on to predried MHA plates. To each plate was placed a single Etest strip (AB Biodisk, Solna, Sweden). All plates were incubated as for the agar dilution and the Etests were read according to manufacturer's guidelines.
Bactericidal assay
To investigate possible synergic activity between PPIs and antibiotics, combinations of PPI and antibiotic at 1 MIC were compared with 1 MIC of each agent alone with respect to bactericidal activity. A modification of methods of Coudron et al. 2 and NCCLS document M26-T 3 were used. Our previous studies had found that Wilkins-Chalgren anaerobe broth (Oxoid, Basingstoke, UK) supplemented with 0.5% (2,6-di-O-methyl)--cyclodextrin (WCC) gave optimal growth of H. pylori in broth culture. Test organisms were subcultured twice in WCC to ensure good growth. Growth was checked by turbidity and viability was checked by examining a drop of broth culture under a phase contrast microscope ( 40 objective) for motile bacilli. One millilitre of fresh overnight broth culture was added to 9 mL of WCC medium with and without antibiotics. Serial ten-fold dilutions of these broths were made immediately in phosphate-buffered saline (PBS) to represent the initial inoculum. Four 20 L drops of each dilution were placed on to a Columbia agar (BBL, Cockeysville, MD, USA) with 5% horse blood (HBA) plate and incubated in a 5% CO 2 incubator at 35°C for 7 days. The inoculated WCC broths were placed in an anaerobic jar with a microaerobic gas generating kit (Camp Gas Pak, Oxoid, UK) and placed on a 120 rpm rotator in a 35°C warm room. At regular intervals (e.g. 2 h, 4 h, 24 h) after inoculation, the WCC broths were serially diluted in PBS and inoculated on to HBA to determine the viable counts as cfu/mL at each time period. Colony counts were performed at several dilutions at each time but only the dilution giving a readable count of 50 colonies per drop were recorded. The limit of detection for the assay was 13 cfu/mL.
Drugs
The effect of drug concentration on bactericidal activity was examined by comparing the 1 MIC, 5 MIC and 10 MIC concentrations of the two PPIs (omeprazole, lansaprazole), amoxycillin and erythromycin.
Results
The time-kill plots are represented in Figures 1-4 . All drugs except amoxycillin showed marked concentration dependent killing of H. pylori. Erythromycin was the most active with a 6 log 10 decrease in viable count at 5 MIC and 10 MIC within 6 h ( Figure 4 ). Lansoprazole at 10 MIC gave this degree of killing by 6 h whereas omeprazole caused only a 3 log 10 decrease in viable count by this time (Figures 1 and 2 ). Amoxycillin produced a maximal bactericidal effect of approximately 3 log 10 decrease in viable count over 24 h regardless of concentration above MIC (Figure 3 ). H. pylori NCTC 11637, with amoxycillin alone, produced almost a 3 log 10 decrease in viable count after 24 h exposure, compared with a 2.5 log 10 decrease in combination with omeprazole ( Figure 5 ). In contrast, the combination of omeprazole and amoxycillin for the clinical isolate was additive (defined as a 2 log 10 decrease in viable count relative to the most active drug alone) 4 ( Figure 6 ). Neither lansoprazole nor omeprazole in combination with amoxycillin produced complete killing of H. pylori over the 24 h test period for the type strain or the clinical isolate. When the macrolide erythromycin was tested in the same way as amoxycillin (Figure 7) , a 3 log 10 decrease in viable count with lansoprazole and a 2 log 10 decrease with omeprazole occurred after 6 h exposure indicating some degree of synergy. This synergy was not detectable at 24 h as the erythromycin alone had killed H. pylori to the lowest limit of detection.
Discussion
Dual therapies consisting of a PPI and antibiotic are being used successfully to cure patients of their H. pylori infection. Neither PPI nor a single antibiotic alone seems to be clinically effective. These drugs may act together synergistically or additively to kill H. pylori rapidly. Apart from the direct antimicrobial action of PPI/antibiotic combinations, there may be important pharmacokinetic and pharmacodynamic considerations with either or both drugs. Omeprazole has recently been shown to facilitate secretion of clarithromycin into the gastric mucosa and increase its bioavailability. 5 Knowledge of pharmacodynamic characteristics of drugs can improve treatment outcomes. Craig & Ebert stated that if a drug exhibits major concentration-dependent killing, the goal of a dosing regimen would be to maximize drug concentrations. 6 Administration of larger doses would increase peak drug concentrations and enhance bactericidal activity. If a drug produces more time-dependent killing, the goal of a dosing regimen would be to maximize antimicrobial exposure. High concentrations of such drugs would not kill bacteria any faster, therefore the duration of time for which drug concentrations exceed the MIC would be expected to be the major determinant of efficacy with such drugs. Because proton pump inhibitors when used as monotherapy against H. pylori suppress but do not eradicate the organism, it was thought that these agents were bacteriostatic in nature. 7 Both PPIs were clearly bactericidal in this invitro study. In this study, concentration-dependent killing of H. pylori was demonstrated with omeprazole, lansopra-zole and erythromycin. The most active single agent was erythromycin with a 4 log 10 decrease in viable count after 2 h incubation at 5 MIC or greater (Figure 4) . In support of this study macrolides have achieved the highest reported eradication rates to date of any monotherapy. 8 However, the development of resistance to macrolides has been reported in about 20% of patients after treatment, either as monotherapy or in combination with a PPI. 9 Amoxycillin did not show concentration-dependent killing although amoxycillin/PPI activity showed strain variation. A clinical trial of PPI/amoxycillin coadministration with increased infrequency of amoxycillin dosing on H. pylori eradication seems warranted. The in-vitro experiments in this study for PPI and amoxycillin alone and in combination showed some strain variation. The type strain NCTC 11637 was killed more slowly with PPI/amoxycillin combinations than with amoxycillin alone, but for the recent clinical isolate there was an additive effect of PPI and amoxycillin on the rate of organism killing. Clinical trials with PPI and amoxycillin have produced eradication rates of up to 80% with a simple and well tolerated regimen which probably improves patient compliance. 10 The major advantage of PPI/amoxycillin dual therapy is the lack of antimicrobial resistance selection and hence treatment can be repeated, although penicillin allergy precludes its use in some individuals. Treatment of H. pylori infection and peptic ulcer disease with PPI/macrolide is now commonly being used with eradication rates of up to 80% in patients with macrolide sensitive strains. Omeprazole 40 mg once daily and clarithromycin 500 mg tid both for 2 weeks is the most common dual therapy. 11 Previous in-vitro studies of macrolide activity have shown that all are active against H. pylori with MICs of between 0.06 mg/L and 1 mg/L and that spontaneous resistance development is rare at 1 10 9 to 1 10 7 . 12 Few data exist on the use of erythromycin in combination with other drugs for the treatment of H. pylori infection. An early study by Goodwin et al. 13 showed that erythromycin 500 mg qid for 2 weeks and bismuth subcitrate 120 mg qid for 2 weeks achieved clearance of the organism in 65% of subjects. In this present study, erythromycin with a proton pump inhibitor was rapidly bactericidal for H. pylori in vitro, though a recent study has shown that the combination of lansoprazole with macrolides against H. pylori in vitro is generally additive.
14 The use of erythromycin in a treatment regimen would have a cost advantage to patients being much cheaper than the newer macrolides but is known to be associated with higher side-effect rates. Erythromycin has infrequently been used for H. pylori treatment because of its lability in acid. Since PPIs are very effective antisecretory agents and raise intragastric pH, coadministration of these drugs would protect the erythromycin from acid degradation. Proton pump inhibitors are bactericidal against H. pylori in vitro and have complex mechanisms of action including antibacterial and antisecretory activity. Clinical trials are required to examine the effectiveness of dual therapies such as PPI and erythromycin and of various dosing schedules to maximize the eradication of H. pylori from infected individuals. 
